In current preclinical studies, 21 commercially available SCD1 inhibitors have been tested in cancer and metabolic diseases such as type 2 diabetes and hepatic steatosis, and nearly half of them have demonstrated inhibitory effects on cancer cell proliferation and tumor growth [49, 53]. Here, SCD is linked to neoplasm.